Top LP award caps off industry-leading performance across multiple categories at annual Lift Gala
MARKHAM, ON, Dec. 1, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, is proud to announce that it won a total of 10 prestigious awards – more than any other LP – at the 2017 edition of the Canadian Cannabis Awards including Top Licensed Producer.
In addition to Top LP, MedReleaf won a number of other categories including:
Top Indica Flower, Sedamen
Top High CBD Flower, Avidekel
Top High THC Flower, Eran Almog
Top High CBD Oil, Avidekel
"I am incredibly proud of our showing at the Canadian Cannabis Awards this year. Taking top spot in four categories, in addition to Top LP, is a testament to the hard work of every single member of the MedReleaf team and the support of our loyal patient base," noted Neil Closner, CEO of MedReleaf.
MedReleaf rounded out its total of 10 awards with second place finishes in top customer service, packaging, compassionate pricing and top hybrid flower for perennial award-winning strain, Midnight. The Company's Luminarium strain took home third place for top sativa. Each of the awards received by MedReleaf were in voter-driven categories.
"Many of this year's winning MedReleaf varieties – Luminarium, Midnight, Sedamen, Avidekel – have consistently found a place in the top 3 since the inception of the awards. This is further proof of the enduring strength of our portfolio and our expertise in growing a consistently high-quality product," added Closner. "These awards are voted by patients and provide validation of our Medical Grade Standards and commitment to excellence."
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is an R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and carefully cultivated in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf
Forward Looking Statements This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, which can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. The forward-looking information contained in this press release are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events which management believes to be reasonable in the circumstances, including expectations and assumptions regarding the regulatory environment in Canada. Forward-looking information are subject to known and unknown risks and uncertainties, including risks and uncertainties which could cause actual events or results to differ materially from those described in any forward‑looking information, including risks and uncertainties relating to general economic conditions, changes in the regulatory and legal environments relating to cannabis, competition, counterparty risk, as well as those risks and uncertainties and other cautionary statements contained in MedReleaf's Annual Information Form dated June 27, 2017, which is available electronically at www.sedar.com. Any forward-looking information contained herein speaks only as of the date on which it is given and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward‑looking information, whether as a result of new information, future events or otherwise.
SOURCE MedReleaf Corp.
For further information: Dennis Fong, Investor Relations, [email protected], 416-283-9930